A detailed history of Charles Schwab Investment Management Inc transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 485,101 shares of VTYX stock, worth $1.04 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
485,101
Previous 467,203 3.83%
Holding current value
$1.04 Million
Previous $1.08 Million 2.04%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.85 - $3.2 $33,111 - $57,273
17,898 Added 3.83%
485,101 $1.06 Million
Q2 2024

Aug 12, 2024

BUY
$2.31 - $5.59 $190,159 - $460,168
82,320 Added 21.39%
467,203 $1.08 Million
Q1 2024

May 08, 2024

BUY
$1.9 - $10.13 $117,216 - $624,950
61,693 Added 19.09%
384,883 $2.12 Million
Q4 2023

Feb 06, 2024

SELL
$2.08 - $31.18 $83,605 - $1.25 Million
-40,195 Reduced 11.06%
323,190 $798,000
Q3 2023

Nov 08, 2023

BUY
$29.8 - $40.3 $3.22 Million - $4.35 Million
107,997 Added 42.29%
363,385 $12.6 Million
Q2 2023

Aug 09, 2023

BUY
$28.53 - $39.55 $1.6 Million - $2.22 Million
56,121 Added 28.16%
255,388 $8.38 Million
Q1 2023

May 11, 2023

SELL
$29.51 - $46.65 $14,932 - $23,604
-506 Reduced 0.25%
199,267 $6.68 Million
Q4 2022

Feb 13, 2023

BUY
$24.16 - $36.38 $949,753 - $1.43 Million
39,311 Added 24.5%
199,773 $6.55 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $795,056 - $2.43 Million
62,900 Added 64.47%
160,462 $5.6 Million
Q2 2022

Aug 15, 2022

BUY
$11.95 - $18.75 $283,920 - $445,481
23,759 Added 32.19%
97,562 $1.19 Million
Q1 2022

May 13, 2022

BUY
$10.0 - $19.98 $24,820 - $49,590
2,482 Added 3.48%
73,803 $1 Million
Q4 2021

Feb 11, 2022

BUY
$14.2 - $23.07 $1.01 Million - $1.65 Million
71,321 New
71,321 $1.42 Million

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $122M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.